From Lab to Patent Office: The Journey of Synthetic Organisms through Intellectual Property Law

In this blog, Lana El-Etr examines the legal and ethical implications of patenting fully synthetic minimal cells, organisms engineered with only the essential genes for life. While a few Supreme Court decisions provide some guidance, this blog argues for updated patent standards that clearly define what qualifies as synthetic and patentable, guard against monopolization of foundational biological tools, and promote equitable access to medical and biotechnological advancements.

Dr. AI; How AI is Affecting the Medical Industry

In this article, Sarah Saadeh discusses how AI is shaking up the medical field and while helping in some processes is also causing commotion with concerns of harm to patients and breaching the duty of care, potential physician and insurance liability and what the regulatory landscape looks like right now advocates for Human-in-the-Loop regulation.

Redefining Enablement: The Impact of Amgen v. Sanofi on Patent Law and Biotechnology

In this article, Lana El-Etr examines how the Amgen v. Sanofi ruling strengthens the enablement requirement, limiting overly broad genus claims while promoting innovation and ensuring accessibility to scientific advancements. She explores the broader implications of the decision, arguing that it strikes a necessary balance between protecting genuine innovation and preventing monopolies on vaguely defined scientific concepts.

Blog at WordPress.com.

Up ↑